Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary

Plain Language Summary: What is this summary about? This summary describes results from a real-world study that looked at people with a type of blood cancer called acute lymphoblastic leukemia (also known as ALL). People in the study received a medicine called inotuzumab ozogamicin (also known as inotuzumab) and then received a stem cell transplant for their ALL. Researchers looked at how long people in the study lived after their transplant and how many people died for reasons related and unrelated to relapse. They also looked at how many people developed side effects, including a potentially life-threatening condition called veno-occlusive disease or sinusoidal obstruction syndrome (also known as VOD/SOS). What were the results? Over half the people (54%) in this study were alive 18 months after their transplant. Around 2 in 10 (22%) people died within 18 months of their transplant from reasons unrelated to relapse, and around 2 in 10 (24%) people died from reasons related to relapse. Around 1 in 10 (14%) people in this study developed VOD/SOS within 100 days of their transplant. People who received two medicines called alkylators to prepare them for their transplant were more likely to develop VOD/SOS than those who did not. What do the results mean? In this real-world study, the proportion of people with ALL who developed VOD/SOS after taking inotuzumab and receiving a stem cell transplant was similar to what has been observed in clinical trials. However, fewer people in this real-world study died from reasons unrelated to relapse than in clinical trials. People who received two medicines called alkylators to prepare them for their stem cell transplant were more likely to develop VOD/SOS.